The invention relates to a class of novel non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-.kappa.B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) ##STR00001## or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein Z, R, R.sup.4, R.sup.5, R.sup.a, R.sup.b, R.sup.c, and R.sup.d, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.